Highest-materiality recent filing
iRhythm shareholders approve 2026 equity plan, elect directors, remove pass-through voting provision
All nine director nominees elected with strong support; no broker votes on most proposals.
iRhythm Q1 revenue $199.4M (+25.7%), net loss narrows; raises FY2026 outlook
Revenue of $199.4M, up 25.7% YoY; net loss $13.9M ($0.43/sh) vs $30.7M ($0.97/sh) in Q1 2025.
iRhythm dismisses PwC as auditor, hires KPMG for FY2026
Dismissed PricewaterhouseCoopers LLP as independent auditor on March 30, 2026.
iRhythm appoints Jason Patten to board; $300K RSU grant
Jason Patten appointed director and Audit Committee member effective March 12, 2026.
Q4 revenue $208.9M (+27.1% YoY); GAAP net income $5.6M ($0.17 diluted EPS), first positive quarterly net income in company history.
Formed new parent iRhythm Holdings via merger of iRhythm into wholly owned sub; no stockholder vote required under DGCL Section 251(g).
iRhythm issues fall 2025 shareholder outreach presentation; no material new details disclosed
Company furnished investor presentation as part of off-season proxy engagement program.
iRhythm Q3 beat: rev $192.9M up 31% YoY, net loss narrows to $5.2M; FY25 guidance raised
Revenue $192.9M, up 30.7% YoY; gross margin 71.1% (+230bps).
iRhythm Q2 revenue up 26.1% to $186.7M; net loss narrows to $14.2M; raises FY 2025 guidance
Revenue $186.7M (+26.1% YoY); gross margin 71.2% (+130 bps).
iRhythm board: Rubash and Snyderman retire; McGinnis and O'Boyle appointed
Mark Rubash (board since 2016) and Ralph Snyderman (board since 2017) resigned effective July 7, 2025; no disagreement cited.
iRhythm shareholders elect all director nominees, ratify PwC as auditor at 2025 annual meeting
Quorum of 30,038,591 shares (94.1% of eligible) present at May 28, 2025 annual meeting.
iRhythm Q1 revenue up 20% to $158.7M; raises FY 2025 guidance
Revenue $158.7M (+20.3% YoY); gross margin 68.8% (+250 bps).
iRhythm Q4 revenue up 24% to $164.3M; net loss narrows to $1.3M; guides FY2025 revenue $675-685M
Q4 revenue $164.3M (+24% YoY); gross margin 70.0% (+410bps). Net loss $1.3M vs $38.7M loss in Q4 2023.
Director Mojdeh Poul to not seek re-election to iRhythm board at next annual meeting
Mojdeh Poul notified iRhythm she will not stand for re-election when her current term expires.
iRhythm pre-announces FY2024 revenue above guidance; FY2025 outlook $675M-$685M
FY2024 revenue expected slightly above prior guidance of $587.5M (provided Oct 2024).
iRhythm removes evergreen provision from 2016 equity plan, amends Code of Conduct
Board approved amendment to 2016 Equity Incentive Plan removing automatic annual share increase (Evergreen Provision).
iRhythm Q3 revenue $147.5M (+18% YoY); gross margin 68.8% up 260 bps
Revenue $147.5M, up 18% YoY; gross profit $101.5M (+23%); gross margin 68.8% vs 66.2%
iRhythm issues shareholder engagement presentation; no material new disclosures
Presentation covers business overview, YTD accomplishments, governance, executive compensation, and sustainability.
iRhythm licenses BioIntelliSense sensor tech for up to $35M + royalties; reaffirms FY2024 guidance
iRhythm pays $15M upfront and up to $20M in milestone payments for an exclusive ACM license of pulse oximetry, accelerometry, and non-invasive BP tech.
iRhythm Q2 revenue $148M (+19.3% YoY), raises FY24 guidance; names new CFO
Revenue of $148.0M, up 19.3% YoY; gross margin 69.9% (+40 bps YoY).
iRhythm say-on-pay vote fails with majority against; all 9 directors re-elected
Say-on-pay advisory proposal on NEO compensation rejected: 13.8M for vs 14.5M against.
Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).
On January 23, 2025, Mojdeh Poul notified iRhythm Technologies, Inc. (the “Company”) of her decision to not seek re-election to the Board of Directors of the Company (the “Board”) at the expiration of her current term, which term ends on the date of the Company’s next annual meeting of stockholders.
On July 31, 2024, the Board of Directors (the “Board”) of the Company appointed Daniel Wilson as the Company’s Chief Financial Officer and principal financial officer, effective as of August 31, 2024.
On August 1, 2024, iRhythm Technologies, Inc. (the “Company”) announced that Brice Bobzien resigned from his position as Chief Financial Officer of the Company, and his employment with the Company, effective August 31, 2024 (the “Separation Date”).
Max materiality 0.85 · Median 0.60 · Most common event other_material